Leading the way to safer medication
 Crosscheck  Recommender

Calcium gluconate

Therapeutic Indications

Calcium gluconate is indicated for:

Osteomalacia

Irrespective of gender only Adults (18 - 65 years old)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 800 mg in 4 divided doses daily

Hypocalcaemic tetany

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 950-4850 mg

Fluoride poisoning, lead poisoning

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 30 mg/kg

Acute hypocalcaemia

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 950-1900 mg

Osteoporosis

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 800 mg in 4 divided doses daily

Cardiac resuscitation

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 665-1425 mg

Neonatal tetany

Irrespective of gender only Newborns (0 - 40 days old)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 30 mg/kg

Contraindications

Active ingredient Calcium gluconate is contraindicated in the following cases:

Severe renal failure

No gender/age discrimination

Cardiac glycosides

No gender/age discrimination

The effects of digoxin and other cardiac glycosides may be potentiated by calcium, which may result in serious toxicity. Therefore, intravenous administration of calcium preparations to patients under therapy with cardiac glycosides is contraindicated.

Hypercalcaemia, hypercalciuria, hyperparathyroidism, hypervitaminosis D, bone metastasis, immobilisation osteoporosis

No gender/age discrimination

  • Patients with hypercalcemia (e.g. in hyperparathyroidism, hypervitaminosis D, a neoplastic disease with decalcification of bone, renal insufficiency, immobilization osteoporosis, sarcoidosis, milk-alkali syndrome);
  • Patients with hypercalciuria;

Ceftriaxone

Irrespective of gender only Newborns (0 - 40 days old)

Co-administration with ceftriaxone in:

    • premature newborns up to a corrected age of 41 weeks (weeks of gestation + weeks of life) and
    • full-term newborns (up to 28 days of age) because of the risk of precipitation of ceftriaxone-calcium

Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and full-term newborns aged less than 1 month have been described. At least one of them had received ceftriaxone and calcium at different times and through different intravenous lines. In the available scientific data, there are no reports of confirmed intravascular precipitations in patients, other than newborns, treated with ceftriaxone and calcium-containing solutions or any other calcium-containing products. In vitro studies demonstrated that newborns have an increased risk of precipitation of ceftriaxone-calcium compared to other age groups.

In patients of any age ceftriaxone must not be mixed or administered simultaneously with any calcium-containing IV solutions, even via different infusion lines or at different infusion sites.

However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be administered sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation. (see sections 4.3, 4.8, and 6.2). Sequential infusions of ceftriaxone and calcium-containing products must be avoided in case of hypovolaemia.